Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).

@article{Mahler2016LongtermSO,
  title={Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).},
  author={Donald A. Mahler and Alex H. Gifford and Aditi Satti and Nicola Jessop and Joerg H. Eckert and Peter D'Andrea and Fernando Mota and Rudrani Banerjee},
  journal={Respiratory medicine},
  year={2016},
  volume={115},
  pages={39-45}
}
BACKGROUND Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the United States. Long-acting muscarinic antagonists (LAMAs) are a class of medications used as maintenance therapy for COPD. The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrrolate (GLY) 15.6 μg twice daily (b.i.d.), compared with an approved long-acting β2-agonist (LABA), indacaterol (IND) 75 μg once daily (q.d.) in… CONTINUE READING